MEDIA RESOURCES
For all media requests please email us at pr@breakthroughcancer.org or call today: 1-800-757-9881 ext.1.
TEAMLAB PUBLICATIONS
2024 PUBLISHED
Adjei, N, Haas, A, Sun, C, et al. Cost of ovarian cancer by the phase of care in the United States. 2024. American Journal of Obstetrics & Gynecology Read More
Aguirre, A, Stanger, B, Maitra, A, et al. Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer. 2024. Cancer Research. Read More
Bahrambeigi, V, Lee, J, Branchi, V, et al. Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-Specific Transcriptome and Molecular Subtype. 2024. Cancer Research. Read More
Braxton, A, Kiemen, A, Grahn, M, et al. 3D genomic mapping reveals multifocality of human pancreatic precancers. 2024. Nature. Read More
Chien, Y, Wang, Y, Huang, P, et al. Morphologic and Molecular Heterogeneity of High-grade Serous Carcinoma Precursor Lesions. 2024. The American Journal of Surgical Pathology. Read More
Dilly, J, Hoffman, M, Abbassi, L, et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. 2024. Cancer Discovery. Read More
Jiang, J, Liu, Y, Qin, J, et al. METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics. 2024. Nature Communications. Read More
Kiemen, A, Wu, P, Braxton, A, et al. Power-law growth models explain incidences and sizes of pancreatic cancer precursor lesions and confirm spatial genomic findings. 2024. Science Advances. Read More
Shi, H, Williams, M, Satas, G, et al. Allele-specific transcriptional effects of subclonal copy number alterations enable genotype-phenotype mapping in cancer cells. 2024. Nature Communications. Read More
Singhal, A, Styers, H, Rub, J, et al. A classical epithelial state drives acute resistance to KRAS inhibition in pancreas cancer. 2024. Cancer Discovery. Read More
Wang, Y, Douville, C, Chien, Y, et al. Aneuploidy Landscape in Precursors of Ovarian Cancer. 2024. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. Read More
Wasko, U, Jiang, J, Dalton, T, et al. Tumor-selective activity of RAS-GTP inhibition in pancreatic cancer. 2024. Nature. Read More
Yen, J, Wu, T, Stone, R, et al. Salpingectomy for ectopic pregnancy reduces ovarian cancer risk—a nationwide study. 2024. JNCI Cancer Spectrum. Read More
Zhang, D, Schroeder, A, Yan, H, et al. Inferring super-resolution tissue architecture by integrating spatial transcriptomics with histology. 2024. Nature Biotechnology. Read More
2024 PRE-PRINT
Chukwu, W, Lee, S, Crane, A, et al. Comparison of germline and somatic structural variants in cancers reveal systematic differences in variant generating and selection processes. 2024. (preprint – bioRxiv) Read More
Huang, J, Yuan, C, Jiang, J, et al. MorphLink: Bridging Cell Morphological Behaviors and Molecular Dynamics in Multi-modal Spatial Omics. 2024. (preprint – bioRxiv) Read More
Kiemen, A, Almagro-Pérez, C, Matos, V, et al. 3D histology reveals that immune response to pancreatic precancers is heterogeneous and depends on global pancreas structure. 2024. (preprint – bioRxiv) Read More
Uryu, H, Saeki, K, Haeno, H, et al. Clonal evolution of hematopoietic stem cells after cancer chemotherapy. 2024. (preprint – bioRxiv) Read More
Wala, J, Bruijn, I, Coy, S, et al. Integrating spatial profiles and cancer genomics to identify immune-infiltrated mismatch repair proficient colorectal cancers. 2024. (preprint – bioRxiv) Read More
Williams, M, Vazquez-Garcia, I, Tam, G, et al. Tracking clonal evolution of drug resistance in ovarian cancer patients by exploiting structural variants in cfDNA. 2024. (preprint – bioRxiv) Read More
Xu, E, Smith, B, Alberto, W, et al. Peptide-MHC-targeted retroviruses enable in vivo expansion and gene delivery to tumor-specific T cells. 2024. (preprint – bioRxiv) Read More
Zhang, C, Pellman, D, et al. Chromosome breakage-replication/fusion enables rapid DNA amplification. 2024. (preprint – bioRxiv) Read More
Zhang, H, Sashittal, P, Karnoub, E, et al. Genomic evolution of pancreatic cancer at single-cell resolution. 2024. (preprint – bioRxiv) Read More
2023 PUBLISHED
Han, J, Xu, J, Liu, Y, et al. Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer. 2023. Genes & Development. Read More
Jazaeri, A, Grisham, R, Knisely, A, et al. Transforming ovarian cancer care by targeting minimal residual disease. 2023. Med. Read More
Mahadevan, K, LeBleu, V, Ramirez, E, et al. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. 2023. Developmental Cell. Read More
Mahadevan, K, McAndrews, K, LeBleu, V, et al. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. 2023. Cancer Cell. Read More
Stone, R, Sakran, J, Long Roche, K, et al. Salpingectomy in Ovarian Cancer Prevention. 2023. JAMA. Read More
Taylor, M, Wu, C, Fridy, P, et al. Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker. 2023. Cancer Discovery. Read More
Zhang, H, Hunter, M, Chou, J, et al. BayesTME: An end-to-end method for multiscale spatial transcriptional profiling of the tissue microenvironment. 2023. Cell Systems. Read More
Zhao, Y, O’Keefe, C, Hsieh, K, et al. Multiplex Digital Methylation‐Specific PCR for Noninvasive Screening of Lung Cancer. 2023. Advanced Science. Read More
2023 PRE-PRINT
Brodeur, M, Dopeso, H, Zhu, Y, et al. Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity. 2023. (preprint – bioRxiv) Read More
Dalin, S, Webster, S, Sugawara, N, et al. Double-strand break repair-associated intragenic deletions and tandem duplications suggest the architecture of the repair replication fork. 2023. (preprint – bioRxiv) Read More
Mahadevan, K, McAndrews, K, LeBleu, V, et al. Oncogenic KrasG12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8+ T cells dependent manner. 2023. (preprint – bioRxiv) Read More
Perelli, L, Zhang, L, Mangiameli, S, et al. Evolutionary fingerprints of EMT in pancreatic cancers. 2023. (preprint – bioRxiv) Read More
Rendo, V, Schubert, M, Khuu, N, et al. A compendium of Amplification-Related Gain Of Sensitivity (ARGOS) genes in human cancer. 2023. (preprint – bioRxiv) Read More
Yu, K, Basu, S, Baquer, G, et al. Investigative needle core biopsies for multi-omics in Glioblastoma. 2023. (preprint – medRxiv) Read More
2022 PUBLISHED
Chatterjee, F, Duong, E, Bhutkar, A, et al. 994 Investigating the ability of tumor cell-derived type I interferon to potentiate anti-ovarian cancer immune responses. 2022. Journal for ImmunoTherapy of Cancer. Read More
Liberto, J, Chen, S, Shih, I, et al. Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review. 2022. Cancers. Read More
Mandal, J, Mandal, P, Wang, T, et al. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. 2022. Journal of Biomedical Science. Read More
2022 PRE-PRINT
Kinny-Köster, B, Guinn, S, Tandurella, J, et al. Inflammatory Signaling in Pancreatic Cancer Transfers Between a Single-cell RNA Sequencing Atlas and Co-Culture. 2022. (preprint – bioRxiv) Read More
NEWS COVERAGE
New collaborative effort aims to cure ALK-positive lung cancer | News Medical
Break Through Cancer launches the PoweRD 2 Cure ALK+ Lung Cancer TeamLab | The Cancer Letter
Radical Collaboration: Reimagining Cancer Team Science | Nature Discovery
Breakthroughs In The Battle Against Cancer With Tyler Jacks | Health Gig Podcast
Removing fallopian tubes can prevent ovarian cancers without causing menopause. But who’s eligible? | WBUR
More physicians are calling for fallopian tube removal to prevent ovarian cancer | STAT
Calls grow for fallopian tube removal to prevent ovarian cancer – The Boston Globe
Fallopian tube removal advised for more women to prevent ovarian cancer | Washington Post
Break Through Barriers To Drive Progress: Cancer Moonshot Pathways | Forbes
Jesse Boehm Discusses Tackling Rare Cancers Using CRISPR
Biden requests $6.5B to fund cancer-focused ARPA-H, an advanced research agency to be housed within NIH | The Cancer Letter
Cancer Matters with Dr Bill Nelson – Tyler Jacks from Break Through Cancer
Breaking Through Cancer: Collaborative translational research goes nationwide | Richmond Times-Dispatch
Dana-Farber, MIT partner on $250M effort to cure most challenging cancers | Boston Business Journal
Cancer Matters with Dr. Bill Nelson – Break Through Cancer
The Chronicle of Philanthropy: A roundup of notable gifts compiled by the Chronicle
Philanthropy News Digest: $250 million gift launches cancer research foundation
Survivor Net: Top 5 Cancer Centers Team Up after a $250 Million Contribution — Incredible Family Behind One of the Largest Donations for Cancer Research talks to SurvivorNet
$250m Philanthropic Capital Infusion Launches Break Through Cancer Targeting Cures for Most Intractable Cancers
The Bidens announce initiatives on health inequity and DARPA-like research for cancer
PRESS RELEASES
Break Through Cancer and Revolution Medicines Collaborate to Study Biomarkers for RAS(ON) Inhibitor in Pancreatic Cancer
Break Through Cancer Launches Team to Prevent Lung Cancer Recurrence with the Hope of Long-term Cures.
Break Through Cancer Announces First Patient Enrolled in Phase 2 Trial Targeting Residual Disease in AML
No More “Wait and See”: Two Clinical Trials Target the Origins of Recurrent Ovarian Cancer
Break Through Cancer and ALK Positive, Inc. Team Up to Conquer ALK-Positive Lung Cancer with a $2 Million, Multi-year, Research Partnership
Reimagining Cancer Team Science: Six Hallmarks of Cancer Collaboration
BE PART OF THE MISSION
Stay Informed, Make an Impact
Subscribe
Be the first to hear about cutting-edge research, pioneering projects, and the latest advancements in Break Through Cancer science. Sign up to stay informed.
Give
Your contribution fuels groundbreaking research in some of the most challenging cancers. Every gift accelerates progress. For more information please contact Michaela Forand at MF@breakthroughcancer.org or 1-800-757-9881 ext 709.